Merck & ChemLex Collaborate to Innovate Chemical Research with AI and Automation

Merck & ChemLex Forge Innovative Alliance in Chemical Research

On January 20, 2026, Merck, a leader in science and technology, announces a strategic collaboration with ChemLex, an innovative Singapore-based company specializing in AI-driven automated chemical synthesis. This partnership, formalized through a Memorandum of Understanding (MOU), aims to transform research and development processes in life sciences and electronics by integrating automated experimentation with advanced chemistry workflows. The collaboration seeks to enhance the speed, efficiency, and reproducibility of chemical research across Merck's diverse sectors, leveraging ChemLex's cutting-edge automated chemistry platform and data generation capabilities.

The initial focus areas for this collaboration include automated synthesis, reaction optimization, high-throughput experimentation, and the integration of chemistry platforms. Merck’s President in China, Marc Horn, emphasizes that this partnership reflects the company's commitment to digital transformation and innovation, with the ultimate goal of creating greater value for its customers. By harnessing the power of AI and automation, both firms are poised to push the boundaries of chemical research, aiming for significant advancements in discovery and development phases.

ChemLex’s Founder and CEO, Dr. Sean Lin, highlights the potential of their proprietary chemical synthesis platform, which operates continuously with an AI feedback mechanism. This technology is expected to allow for validation and optimization in a wider range of application scenarios. The MOU signifies a mutual interest in scalable, data-rich experimental science and indicates a shared vision for long-term partnerships, fostering innovation at the intersection of chemistry and automation. As discussions continue, both companies are set to evaluate future steps within the MOU framework, laying the groundwork for a promising collaboration that could redefine the landscape of chemical research.

In addition to enhancing research capabilities, this strategic alliance positions Merck to remain competitive in a rapidly evolving industry that increasingly relies on automation and advanced technologies. The integration of ChemLex’s AI-driven solutions is likely to streamline Merck's R&D processes, ensuring that the company remains at the forefront of scientific innovation.

As Merck explores this partnership, it underscores the broader trend within the life sciences sector towards adopting digital tools and automation to accelerate discovery and improve outcomes. The collaboration with ChemLex is a testament to Merck's proactive approach to innovation, aiming to leverage cutting-edge technology to meet the evolving demands of the industry.